4 Stocks Pushing The Drugs Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 39 points (-0.3%) at 13,960 as of Monday, Feb. 25, 2013, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,475 issues advancing vs. 1,392 declining with 148 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Gilead ( GILD), up 1.3%, Novartis ( NVS), up 0.6% and Novo Nordisk A/S ( NVO), up 0.6%. On the negative front, top decliners within the industry include GlaxoSmithKline ( GSK), down 1.2%, and Celgene Corporation ( CELG), down 0.8%.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry higher today:

4. Perrigo Company ( PRGO) is one of the companies pushing the Drugs industry higher today. As of noon trading, Perrigo Company is up $3.44 (3.0%) to $116.75 on average volume Thus far, 458,077 shares of Perrigo Company exchanged hands as compared to its average daily volume of 786,700 shares. The stock has ranged in price between $115.30-$116.90 after having opened the day at $115.71 as compared to the previous trading day's close of $113.31.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API) worldwide. Perrigo Company has a market cap of $10.7 billion and is part of the health care sector. The company has a P/E ratio of 24.6, above the S&P 500 P/E ratio of 17.7. Shares are up 9.2% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Perrigo Company a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Perrigo Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, reasonable valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Perrigo Company Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, Eli Lilly and Company ( LLY) is up $0.42 (0.8%) to $54.68 on light volume Thus far, 2.2 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 6.9 million shares. The stock has ranged in price between $54.39-$54.93 after having opened the day at $54.50 as compared to the previous trading day's close of $54.27.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $62.7 billion and is part of the health care sector. The company has a P/E ratio of 14.8, below the S&P 500 P/E ratio of 17.7. Shares are up 9.5% year to date as of the close of trading on Friday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 3 analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Company Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Amgen ( AMGN) is up $3.80 (4.4%) to $90.62 on heavy volume Thus far, 5.2 million shares of Amgen exchanged hands as compared to its average daily volume of 5.4 million shares. The stock has ranged in price between $89.30-$91.25 after having opened the day at $89.30 as compared to the previous trading day's close of $86.82.

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Amgen has a market cap of $65.3 billion and is part of the health care sector. The company has a P/E ratio of 15.2, below the S&P 500 P/E ratio of 17.7. Shares are down 1.2% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Abbott Laboratories ( ABT) is up $0.10 (0.3%) to $34.65 on light volume Thus far, 2.4 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 13.8 million shares. The stock has ranged in price between $34.59-$34.84 after having opened the day at $34.60 as compared to the previous trading day's close of $34.55.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $53.8 billion and is part of the health care sector. The company has a P/E ratio of 9.2, below the S&P 500 P/E ratio of 17.7. Shares are up 4.6% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Abbott Laboratories Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null